Construction of biomarker in urological cancer targeting the O-glycan
Project/Area Number |
24791631
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Urology
|
Research Institution | Hirosaki University |
Principal Investigator |
Tobisawa Yuki 弘前大学, 医学(系)研究科(研究院), 助教 (70623768)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
Keywords | 糖転移酵素 / 糖鎖生物学 / バイオマーカー / 前立腺癌 / 糖鎖抗原 / モノクローナル抗体 / 癌 / マーカー |
Outline of Final Research Achievements |
Core2 β-1,6-N-acetylglucosaminyltransferase-1 (GCNT1) is a key enzyme that forms core 2-branched O-glycans.Paraffin-embedded PCa specimens were analyzed by immunohistochemistry for GCNT1 expression. GCNT1-negative tumors were associated with significantly better prostate-specific antigen (PSA)-free survival compared with GCNT1-positive tumors. Multivariate analysis revealed that detection of GCNT1 expression was an independent risk factor for PSA recurrence. We established new methods for GCNT1 detection from PCa specimens. Immunoblotting was used to examine post-digital rectal examination (DRE) urine from PCa patients. Over 90% of GCNT1-positive PCa patients with high concentrations of PSA showed extracapsular extension. In conclusion, GCNT1 expression closely associates with the aggressive potential of PCa. Further research aims to develop GCNT1 detection in post-DRE urine as a marker for PCa aggressiveness.
|
Report
(4 results)
Research Products
(20 results)
-
[Journal Article] Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.2015
Author(s)
Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y.
-
Journal Title
Int J Clin Oncol.
Volume: 20(1)
Issue: 1
Pages: 176-81
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
[Journal Article] Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.2014
Author(s)
Yoneyama T, Ohyama C, Hatakeyama S, Narita S, Habuchi T, Koie T, Mori K, Hidari KI, Yamaguchi M, Suzuki T, Tobisawa Y
-
Journal Title
Biochem Biophys Res Commun.
Volume: 448
Issue: 4
Pages: 390-396
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Serum tri-and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer.2014
Author(s)
Ishibashi Y, Tobisawa Y, Hatakeyama S, Ohashi T, Tanaka M, Narita S, Koie T, Habuchi T, Nishimura S, Ohyama C, Yoneyama T
-
Journal Title
Prostate
Volume: 74
Issue: 15
Pages: 1521-1529
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.2014
Author(s)
Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y.
-
Journal Title
Int J Clin Oncol
Volume: not yet
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
-
-
-
-
[Presentation] 糖転移酵素C2GnTは前立腺癌と間質細胞との相互作用を高め前立腺癌の増殖を制御する2013
Author(s)
飛澤悠葵, 米山 徹, 盛 和行, 畠山真吾, 今井 篤, 岡本亜希子, 山本勇人, 杉山尚樹, 岡本哲平, 鈴木裕一朗, 萩原和久, 及川真亮, 成田拓磨, 米山高弘, 橋本安弘,古家琢也, 大山 力
Organizer
第22回泌尿器科分子・細胞研究会
Place of Presentation
高知
Related Report
-
-
-
-
-
-
-